ANIX
Anixa Biosciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Beats Expectation
Price Hits 52-week Low
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ANIX
Anixa Biosciences, Inc.
A biotechnology company focused on the treatment and prevention of cancer and infectious diseases
3150 Almaden Expressway, Suite 250, San Jose, CA 95118
--
Anixa Biosciences, Inc., incorporated under the laws of the State of Delaware on November 5, 1982, is a biotechnology company dedicated to the development of therapies and vaccines for critical unmet needs in oncology and infectious diseases. The company's main business is the development of chimeric endocrine receptor T cell technology and the discovery and eventual development of anticancer drugs - viral drug candidates for the treatment of COVID - 19 focus on inhibiting certain viral protein functions of the virus.
Company Financials
EPS
ANIX has released its 2025 Q3 earnings. EPS was reported at -0.07, versus the expected -0.1, beating expectations. The chart below visualizes how ANIX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
